Filter by Category: In Vitro Activity

Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018.

Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018. by Castanheira M, Doyle TB, Kantro V, Mendes RE and Shortridge D published in Antimicrob. Agents Chemother. 2020; 64 (2): 01951

Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018

Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018. by Carvalhaes CG, Shortridge D, Sader HS and Castanheira M. published in Antimicrobial agents and chemotherapy. in press, 2020.

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2019; 96: 114833

In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018.

In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. by Flamm RK, Shortridge D, Castanheira M, Sader HS and Pfaller MA. published in Antimicrob. Agents. Chemother. 63 (11): e01154, 2019.

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States. Lead author: S Paukner, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 703

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA)

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA). Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #681

Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018

Comparison of cefepime-zidebactam (WCK 5222), ceftazidime-avibactam, and ceftolozane-tazobactam tested against Gram-negative organisms causing pneumonia in United States hospitals in 2018. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2214

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals

Minocycline Activity against Stenotrophomonas maltophilia Isolated from Patients in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1584

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections. Lead author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 1436

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018)

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018). Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1582